Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil
- PMID: 17968461
- DOI: 10.1111/j.1745-7262.2007.00319.x
Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil
Abstract
Aim: To evaluate patient preferences for sildenafil citrate or tadalafil (PDE-5 inhibitors available for the treatment of erectile dysfunction [ED]) and assess potential reasons for these preferences.
Methods: This open-label study was conducted on Korean men taking sildenafil, at least 6 weeks prior to study entry, for ED. Following screening, patients continued sildenafil treatment for 4 weeks, then after a 1-week washout period, switched to tadalafil for 8 weeks. Patients then continued with their treatment of choice during an extension phase. Psychosocial factors (time concern, spontaneity, sexual self-confidence) were evaluated using Psychological and Interpersonal Relationship Scales (PAIRS), while timing of dose to sexual attempt patterns were assessed from patient diaries.
Results: The present study enrolled 160 Korean men (mean age 55 years) with prior median sildenafil use of 585 days. During the extension phase, 73.7% of patients elected to take tadalafil, whereas 26.3% chose sildenafil (P < 0.001). After switching from sildenafil to tadalafil, mean PAIRS time concern scores decreased from 2.54 to 2.42 (P = 0.002), with no statistically significant differences observed between the sildenafil and tadalafil assessment phases in sexual spontaneity and self-confidence scores. Sexual attempts made > 4 h to =/< 36 h post-dose occurred in 4.5% of patients during the sildenafil assessment phase compared with 17.5% during the tadalafil assessment phase.
Conclusion: After experiencing both sildenafil and tadalafil, the majority of patients exhibited a preference for tadalafil. This preference might be influenced by psychosocial factors, such as decreased time concerns, and a broader window of opportunity available for sexual activity.
Similar articles
-
Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.BJU Int. 2007 Jul;100(1):122-9. doi: 10.1111/j.1464-410X.2007.06916.x. BJU Int. 2007. PMID: 17552960 Clinical Trial.
-
The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.BJU Int. 2007 Feb;99(2):376-82. doi: 10.1111/j.1464-410X.2006.06586.x. Epub 2006 Nov 28. BJU Int. 2007. PMID: 17155989
-
Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.Pak J Pharm Sci. 2008 Jul;21(3):275-81. Pak J Pharm Sci. 2008. PMID: 18614424 Clinical Trial.
-
Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Int J Impot Res. 2007 May-Jun;19(3):281-95. doi: 10.1038/sj.ijir.3901525. Epub 2006 Dec 21. Int J Impot Res. 2007. PMID: 17183346 Review.
-
Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra).Urology. 2006 Sep;68(3 Suppl):26-37. doi: 10.1016/j.urology.2006.06.027. Urology. 2006. PMID: 17011373 Review.
Cited by
-
Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction.J Zhejiang Univ Sci B. 2011 Jun;12(6):455-9. doi: 10.1631/jzus.B1000363. J Zhejiang Univ Sci B. 2011. PMID: 21634038 Free PMC article.
-
Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis.Asian J Androl. 2009 Jul;11(4):423-33. doi: 10.1038/aja.2009.11. Epub 2009 Apr 20. Asian J Androl. 2009. PMID: 19377488 Free PMC article.
-
Erectile dysfunction - an update of current practice and future strategies.J Clin Urol. 2013 Jul;6(4):210-219. doi: 10.1177/2051415813491862. J Clin Urol. 2013. PMID: 26097710 Free PMC article. No abstract available.
-
Practical Approaches to Treat ED in PDE5i Nonresponders.Aging Dis. 2020 Oct 1;11(5):1202-1218. doi: 10.14336/AD.2019.1028. eCollection 2020 Oct. Aging Dis. 2020. PMID: 33014533 Free PMC article. Review.
-
Evolution of Phosphodiesterase-5 Inhibitors.World J Mens Health. 2015 Dec;33(3):123-4. doi: 10.5534/wjmh.2015.33.3.123. Epub 2015 Dec 23. World J Mens Health. 2015. PMID: 26770931 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical